KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Year-over-year research & development expense growth
Latest
-20.90%
↓ 183% vs avg
Percentile
P8
Near historical low
Streak
2 qtr
Consecutive declineDecelerating
Average
25.28%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | -20.90% |
| Q3 2025 | -4.59% |
| Q2 2025 | 26.18% |
| Q1 2025 | -24.18% |
| Q4 2024 | -37.59% |
| Q3 2024 | 5.41% |
| Q2 2024 | 12.10% |
| Q1 2024 | 17.99% |
| Q4 2023 | -1.13% |
| Q3 2023 | -19.39% |
| Q2 2023 | 19.38% |
| Q1 2023 | 10.99% |
| Q4 2022 | -0.60% |
| Q3 2022 | -5.35% |
| Q2 2022 | -2.66% |
| Q1 2022 | 12.49% |
| Q4 2021 | 28.36% |
| Q3 2021 | 15.09% |
| Q2 2021 | 30.56% |
| Q1 2021 | -0.56% |
| Q4 2020 | -18.07% |
| Q3 2020 | 17.71% |
| Q2 2020 | -15.56% |
| Q1 2020 | 14.75% |
| Q4 2019 | 1.06% |
| Q3 2019 | -13.04% |
| Q2 2019 | 45.61% |
| Q1 2019 | -2.87% |
| Q4 2018 | -5.74% |
| Q3 2018 | 42.79% |
| Q2 2018 | 28.67% |
| Q1 2018 | 4.29% |
| Q4 2017 | 25.46% |
| Q3 2017 | 16.02% |
| Q2 2017 | -10.27% |
| Q1 2017 | 905.72% |
| Q3 2016 | 0.00% |
| Q2 2016 | -90.60% |
| Q1 2016 | -17.09% |
| Q4 2015 | 20.58% |